Non-genetic mechanisms have recently emerged as important drivers of anticancer drug
resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more …

Colorectal cancer (CRC) is traditionally considered to be a genetically driven disease.
However, nongenetic plasticity has recently emerged as a major driver of tumour initiation …

Molecular stratification using gene-level transcriptional data has identified subtypes with
distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular …

Patient-derived organoids (PDOs) can model personalized therapy responses; however,
current screening technologies cannot reveal drug response mechanisms or how tumor …

Hepatoblastoma, the most prevalent pediatric liver cancer, almost always carries a WNT-
activating CTNNB1 mutation, yet exhibits notable molecular heterogeneity. To characterize …

Genomic instability, a hallmark of cancer, is a direct consequence of the inactivation of the
tumor suppressor protein p53. Genetically modified mouse models and human tumor …

Loss-of-function mutations in the tumour suppressor APC are an initial step in intestinal
tumorigenesis 1, 2. APC-mutant intestinal stem cells outcompete their wild-type neighbours …

Colorectal cancer (CRC) has a broad range of molecular alterations with two major
mechanisms of genomic instability (chromosomal instability and microsatellite instability) …

As cancers progress, they become increasingly aggressive—metastatic tumours are less
responsive to first-line therapies than primary tumours, they acquire resistance to successive …

Intra-tumoural heterogeneity and cancer cell plasticity in colorectal cancer (CRC) have been
key challenges to effective treatment for patients. It has been suggested that a subpopulation …